Aldosterone and progression of kidney disease.

Monica Cortinovis, Norberto Perico, Dario Cattaneo, Giuseppe Remuzzi

Research output: Contribution to journalArticlepeer-review


Experimental evidence indicates that aldosterone, besides its mineralcorticoid properties, directly contributes to accelerate renal damage through promotion of cell growth, fibrosis and inflammation. As a consequence, attenuation of growth-promoting and fibroproliferative effects of aldosterone might contribute to slow progression of chronic renal injury. Preliminary clinical observations have documented that aldosterone blockers added to angiotensin-converting enzyme inhibitor- and/or angiotensin receptor blocker-based regimens exerted significant antiproteinuric effects in patients with diabetic and nondiabetic nephropathies. Further studies in larger cohorts are now required to definitively address the safety and efficacy of aldosterone antagonism in patients with chronic kidney diseases.

Original languageEnglish
Pages (from-to)133-143
Number of pages11
JournalTherapeutic Advances in Cardiovascular Disease
Issue number2
Publication statusPublished - Apr 2009

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)


Dive into the research topics of 'Aldosterone and progression of kidney disease.'. Together they form a unique fingerprint.

Cite this